AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019

February 27, 2019

Heidelberg, Germany, February 27, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system, today announced that two abstracts from the Company’s innate cell engager program have been accepted for poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA.

AFM24 (EGFR/CD16A)

AFM24, in development for the treatment of patients with a variety of EGFR-expressing solid tumors, is designed to address limitations associated with other EGFR-targeting therapies, such as toxicities or resistances. Data highlighting the differentiating features of AFM24 will be presented, including toxicology studies demonstrating a favorable safety profile.

Poster Presentation Details:

Abstract: Preclinical characterization of the bispecific EGFR/CD16A innate immune cell engager AFM24 for the treatment of EGFR-expressing solid tumorsSession: Therapeutic Antibodies 1Date and Time: Sunday March 31, 2019 1:00 PM - 5:00 PM (ET)Location: Georgia World Congress Center, Exhibit Hall B

AFM13 (CD30/CD16A)

An adoptive immunotherapy approach with AFM13-loaded cord blood-derived NK cells has recently been preclinically established and appears to be a promising approach to treating patients with relapsed/refractory CD30-positive malignancies. Further substantiating Affimed’s rationale for combining AFM13 with activated NK cell-based therapies, together with its collaboration partners from Washington University School of Medicine, Saint Louis, MO, Affimed will present data aimed at describing NK cell functional responses to tumor cells triggered via AFM13.

Poster Presentation Details:

Abstract: The CD30/CD16A bispecific innate immune cell engager AFM13 elicits heterogeneous single-cell NK cell responses and effectively triggers memory-like (ML) NK cellsSession: Therapeutic Antibodies 2Date and Time: Monday April 1, 2019 8:00 AM - 12:00 PM (ET)Location: Georgia World Congress Center, Exhibit Hall B

Full abstracts of the presentations can be accessed on the AACR website at www.aacr.org.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company that engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat cancers. For more information, please visit www.affimed.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the value of our ROCK® platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Affimed Investor Contact:Gregory Gin, Head of Investor RelationsE-Mail: IR@affimed.com

Affimed Media Contact:Anca Alexandru, Head of Communications, EU IRE-Mail: media@affimed.com